Clinical trial
Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed…
NCT00157560 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00157560 |
|---|---|
| Title | Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma |
| Official title | A Phase II Trial of ModifiedTriple Doublet Therapy in the Treatment of Women With Newly Diagnosed Carcinoma of Müllerian Origin |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | GlaxoSmithKline Industry Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Chemotherapy, multiple agents |
| Enrollment | 83 |
| Start date | Dec 1, 2000 |
| Primary completion | Nov 1, 2006 |
| Completion | Jul 1, 2005 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 3, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: